In vitro effects of the glycoprotein IIb/IIIa receptor antagonists abciximab and eptifibatide on platelet aggregation in healthy cats.
Conclusions and Clinical Relevance-Eptifibatide caused a significant reduction in platelet aggregation in vitro, but there was no identifiable antiplatelet effect for abciximab. Eptifibatide and abciximab have different binding and inhibitory actions; therefore, it can be hypothesized that abciximab would be ineffective in cats because of a lack of receptor binding, reduced binding kinetics, or lack of downstream signaling. Eptifibatide may be useful in identifying hyperreactive platelets in cats in an in vitro platelet inhibitory assay.
PMID: 24564318 [PubMed - in process] (Source: American Journal of Veterinary Research)
Source: American Journal of Veterinary Research - March 1, 2014 Category: Veterinary Research Authors: Magee AN, Hogan DF, Sederquist KA, Durham JA Tags: Am J Vet Res Source Type: research
Eptifibatide-induced acute profound thrombocytopenia: a case report
Conclusion:
This report adds another case of eptifibatide-induced thrombocytopenia to the medical literature and endorses the importance of platelet count monitoring after initiating therapy with this agent. (Source: BMC Research Notes)
Source: BMC Research Notes - February 25, 2014 Category: Research Authors: Christos GraidisChristos GoliasDimokritos DimitriadisGeorgios DimitriadisTheodosis BitsisIlias DimitrelosAfroditi TsiakouKonstantinos Charalabopoulos Source Type: research
A Matched Comparison of Eptifibatide Plus rt-PA Versus rt-PA Alone in Acute Ischemic Stroke
Conclusions: The safety and direction of effect of eptifibatide plus rt-PA were confirmed. A phase III trial is needed to determine the efficacy of eptifibatide plus rt-PA for improving long-term outcomes after AIS. (Source: Journal of Stroke and Cerebrovascular Diseases)
Source: Journal of Stroke and Cerebrovascular Diseases - February 19, 2014 Category: Neurology Authors: Opeolu Adeoye, William A. Knight, Jane Khoury, Pamela A. Schmit, Heidi Sucharew, Joseph P. Broderick, Arthur M. Pancioli, CLEAR-ER Investigators Tags: Original Articles Source Type: research
Off-target effects of glycoprotein IIb/IIIa receptor inhibitors.
Abstract
Soon after identification of the platelet membrane glycoprotein (GP) IIb/IIIa receptor and due to its key role in platelet aggregation, it became the target of antithrombotic therapy. There are three intravenous glycoprotein IIb/IIIa receptor inhibitors (GPI) used in clinical practice, particularly in patients with acute coronary syndrome undergoing percutaneous coronary intervention. The aim of the current review is to summarize available knowledge concerning off-target effects of GPI. All three drugs have similar antithrombotic properties, but differ with respect to pharmocodynamics, pharmacokin...
Source: Cardiology Journal - February 14, 2014 Category: Cardiology Authors: Ostrowska M, Adamski P, Koziński M, Navarese EP, Fabiszak T, Grześk G, Paciorek P, Kubica J Tags: Cardiol J Source Type: research
Angiographic Outcomes With Early Eptifibatide Therapy in Non–ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial)
Early administration of glycoprotein IIbIIIa inhibitors results in improved angiographic parameters, including thrombolysis in myocardial infarction (TIMI) flow grade, corrected TIMI frame count, and TIMI myocardial perfusion grade (TMPG) among patients with ST-segment elevation myocardial infarction. Whether the same is true in the setting of non–ST-segment elevation acute coronary syndrome is unknown. The goal of the early glycoprotein IIbIIIa inhibition in non–ST-segment elevation acute coronary syndrome (EARLY ACS) angiographic substudy was to compare angiographic outcomes among patients with non–ST-segment elev...
Source: The American Journal of Cardiology - February 3, 2014 Category: Cardiology Authors: Vijay Kunadian, Robert P. Giugliano, L. Kristin Newby, Cafer Zorkun, Jianping Guo, Akshay Bagai, Gilles Montalescot, Eugene Braunwald, Robert M. Califf, Frans Van de Werf, Paul W. Armstrong, Robert Harrington, C. Michael Gibson Tags: Coronary Artery Disease Source Type: research
The use of eptifibatide for suspected pump thrombus or thrombosis in patients with left ventricular assist devices
Conclusions: Our limited experience indicates the risk of using eptifibatide outweighs the proposed benefit of salvaging the existing LVAD in the setting of suspected pump thrombus/thrombosis at our institution. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - November 27, 2013 Category: Transplant Surgery Authors: Bethany R. Tellor, Jennifer R. Smith, Sunil M. Prasad, Susan M. Joseph, Scott C. Silvestry Tags: Featured Articles Source Type: research
Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy
Conclusions: Among more than 4,000 patients with moderate- and high-risk ACS treated with upstream GPI as part of an early invasive management strategy, the use of tirofiban and eptifibatide resulted in similar clinical outcomes. These data suggest equivalence of these 2 agents for upstream use, while highlighting some of the difficulties of nonrandomized comparative effectiveness analyses, specifically the difficulty in addressing geographic differences in the use of nonrandomized treatments. (Source: American Heart Journal)
Source: American Heart Journal - November 21, 2013 Category: Cardiology Authors: Tamim M. Nazif, Roxana Mehran, Edwin A.M. Lee, Martin Fahy, Helen Parise, Gregg W. Stone, Ajay J. Kirtane Tags: Acute Ischemic Heart Disease Source Type: research
An effect of glycoprotein IIb/IIIa inhibitors on the kinetics of red blood cells aggregation.
Abstract
The reversible aggregation of red blood cells (RBCs) continues to be of the basic science and clinical interest. Recently it has been reported about a specific binding between fibrinogen and unknown erythrocyte glycoprotein receptors. The aim of this study was to investigate whether the red blood cell aggregation (RBCA) include the cell-cell interaction using the membrane receptors that bind such ligands as fibrinogen or fibronectin. To test this hypothesis the RBCs were incubated with monafram - the drug of the monoclonal antibodies against glycoprotein (GP) IIb/IIIa, with the GPIIb-IIIa receptor...
Source: Clinical Hemorheology and Microcirculation - September 30, 2013 Category: Hematology Authors: Sokolova IA, Muravyov AV, Khokhlova MD, Rikova SY, Lyubin EV, Gafarova MA, Skryabina MN, Fedyanin AA, Kryukova DV, Shahnazarov AA Tags: Clin Hemorheol Microcirc Source Type: research
Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: Insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial
Conclusions: In a contemporary high-risk NSTE ACS cohort, women had higher bleeding rates than did men. Paradoxically, the association between bleeding and mortality was worse among men than among women. (Source: American Heart Journal)
Source: American Heart Journal - September 6, 2013 Category: Cardiology Authors: Padma Kaul, Jean-François Tanguay, L. Kristin Newby, Judith S. Hochman, Cynthia M. Westerhout, Robert M. Califf, Pierluigi Tricoci, C. Michael Gibson, Robert P. Giugliano, Robert A. Harrington, Frans Van de Werf, Paul W. Armstrong Tags: Acute Ischemic Heart Disease Source Type: research
Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke-Enhanced Regimen Stroke Trial [Major Clinical Trial]
Conclusions—
The combined regimen of intravenous rt-PA and eptifibatide studied in this trial was safe and provides evidence that a phase III trial is warranted to determine efficacy of the regimen.
Clinical Trial Registration—
URL: http://www.clinicaltrials.gov. Unique identifier: NCT00894803. (Source: Stroke)
Source: Stroke - August 26, 2013 Category: Neurology Authors: Pancioli, A. M., Adeoye, O., Schmit, P. A., Khoury, J., Levine, S. R., Tomsick, T. A., Sucharew, H., Brooks, C. E., Crocco, T. J., Gutmann, L., Hemmen, T. M., Kasner, S. E., Kleindorfer, D., Knight, W. A., Martini, S., McKinney, J. S., Meurer, W. J., Meye Tags: Emergency treatment of Stroke, Antiplatelets, Thrombolysis Major Clinical Trial Source Type: research
A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease
Conclusions: In this small study, eptifibatide appeared to be safe, but did not improve the times to crisis resolution or hospital discharge. Adequately powered studies are required to evaluate the safety and efficacy of eptifibatide in SCD. Clinicaltrials.gov Identifier: NCT00834899. (Source: Thrombosis Research)
Source: Thrombosis Research - August 23, 2013 Category: Hematology Authors: Payal C. Desai, Julia E. Brittain, Susan K. Jones, Adam McDonald, Douglas R. Wilson, Rosalie Dominik, Nigel S. Key, Leslie V. Parise, Kenneth I. Ataga Tags: Clinical Studies Source Type: research
Thrombodynamics of Microvascular Repairs: Effects of Antithrombotic Therapy on Platelets and Fibrin
Conclusions:
These findings show that platelets have a rapid, transient response, whereas fibrin has a slower, more sustained accrual in both arterial and venous anastomoses. Furthermore, inhibition of either coagulation or platelet aggregation can influence presumably non-targeted components of thrombosis in vascular repairs of both arteries and veins.
Clinical relevance:
Preventing replantation failure using antithrombotic therapies requires a better understanding of the effect of each pharmacologic compound on the various aspects of thrombogenesis. (Source: The Journal of Hand Surgery)
Source: The Journal of Hand Surgery - July 29, 2013 Category: Surgery Authors: Glenn Shi, David Meister, Roger A. Daley, Brian C. Cooley Tags: Scientific Articles Source Type: research
Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non–ST-segment elevation acute coronary syndromes patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome trial
Conclusions: Consistent with previous literature, upstream treatment with eptifibatide was associated with improved outcomes in high-risk non–ST-segment elevation acute coronary syndrome patients treated with PCI; however, a nonsignificant interaction term precludes a definite conclusion. (Source: American Heart Journal)
Source: American Heart Journal - July 29, 2013 Category: Cardiology Authors: Akshay Bagai, Jennifer A. White, Yuliya Lokhnygina, Robert P. Giugliano, Frans Van de Werf, Gilles Montalescot, Paul W. Armstrong, Pierluigi Tricoci, C. Michael Gibson, Robert M. Califf, Robert A. Harrington, L. Kristin Newby Tags: Acute Ischemic Heart Disease Source Type: research
